title: Changes in bronchial responsiveness, circulating leucocytes and ex vivo cytokine production by blood monocytes after PAF inhalation in allergic asthmatics.
abstract: We investigated the effects of inhaled platelet-activating factor (PAF) on methacholine bronchial responsiveness, circulating leucocyte counts, and ex vivo tumour necrosis factor alpha (TNF alpha) and interleukin-1 (IL-1) production from blood monocytes in eight allergic asthmatics. Bronchial responsiveness was defined as the provocative concentration of methacholine causing a 20% decrease in forced expiratory volume in one second (PC20). Circulating leucocytes were counted by means of an automatic haemocytometer, and cytokines were measured with specific immunoassays. The different variables were measured before and 4, 24, 48, 72 and 168 h after a PAF (225 micrograms), a lyso-PAF (225 micrograms) and a saline bronchial challenge. When compared with lyso-PAF and saline, inhalation of PAF resulted in a significant decrease in PC20 over a period of one week. Two falls in bronchial responsiveness were identified, the first by 4 h and the second beginning 48 h and reaching a maximum by 168 h. The increases in spontaneous TNF alpha and IL-1 production which occurred during the week after both PAF, lyso-PAF and saline, did not differ significantly. Likewise, the changes in circulating neutrophil counts, characterized by a transient rise by 4 h after PAF and lyso-PAF but not saline, followed by a fall by 24 h and a persistent decrease until 168 h, were not significantly different after PAF, lyso-PAF and saline. On the other hand, in comparison with lyso-PAF and saline, inhaled PAF caused a significant protracted augmentation in circulating eosinophil counts, which was maximal by 48 h but did not correlate with the delayed decline in PC20.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Dept of Pneumology, CHU Sart Tilman, Liege, Belgium.
authors.forename: R
authors.initials: R
authors.lastname: Louis
authors.forename: D
authors.initials: D
authors.lastname: Degroote
authors.forename: T
authors.initials: T
authors.lastname: Bury
authors.forename: J L
authors.initials: JL
authors.lastname: Corhay
authors.forename: J M
authors.initials: JM
authors.lastname: Kayembe
authors.forename: P
authors.initials: P
authors.lastname: Franchimont
authors.forename: M F
authors.initials: MF
authors.lastname: Radermecker
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D001249:Asthma / Q000097:blood / Q000276:immunology / Q000503:physiopathology*; D016535:Bronchial Hyperreactivity / Q000503:physiopathology*; D001985:Bronchial Provocation Tests; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis*; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008297:Male; D016210:Methacholine Chloride; D010972:Platelet Activating Factor / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*; D016037:Single-Blind Method; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
chemical_list: D007375:Interleukin-1; C029271:O-deacetyl platelet activating factor; D010972:Platelet Activating Factor; D014409:Tumor Necrosis Factor-alpha; D016210:Methacholine Chloride